Skip to main content
MBGNF logo

Many Bright Ideas Technologies Inc. (MBGNF) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.0059 $0.00 (0.00%)
Vol: 1.0K| 52-wk range: $0.0059 – $0.01

Beta 1.47: the stock has moved about 47% more than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Many Bright Ideas Technologies Inc. (MBGNF) trades at $0.0059. Many Bright Ideas Technologies Inc. is a Canadian company previously focused on genomic-based tests for non-small-cell lung cancer. Currently, the company aims to commercialize technologies across various industrial sectors. Sector: Healthcare.

Price as of · Last analyzed: Mar 17, 2026
Many Bright Ideas Technologies Inc. is a Canadian company previously focused on genomic-based tests for non-small-cell lung cancer. Currently, the company aims to commercialize technologies across various industrial sectors.

Analyst Coverage for MBGNF: MBGNF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • INBS · Intelligent Bio Solutions Inc. · 19 /100
  • NDRA · ENDRA Life Sciences Inc. · 31 /100
  • VNRX · VolitionRx Limited · 21 /100

See all scored stocks →

Many Bright Ideas Technologies Inc. (MBGNF) Healthcare & Pipeline Overview

CEOIain Weir-Jones
Employees7
HeadquartersVancouver, CA
IPO Year2018

Many Bright Ideas Technologies Inc., formerly Med BioGene Inc., is a Canadian company transitioning from genomic-based tests for lung cancer to commercializing technologies in diverse sectors. With a small market capitalization and negative earnings, the company operates in the evolving medical diagnostics and research industry.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 17, 2026

What Is the Investment Thesis for MBGNF?

AI-written as of Mar 17, 2026 — figures and tone reflect the data available then, not today's score.

Investing in Many Bright Ideas Technologies Inc. presents a high-risk, high-reward scenario. The company's transition from a focused life science business to a broader technology commercialization entity introduces significant uncertainty. Key value drivers hinge on successful identification and commercialization of new technologies, which are currently undefined. The company's negative P/E ratio of -2.02 reflects its lack of profitability, and its small market capitalization of $0.00B indicates limited investor confidence. A potential growth catalyst is the successful launch of a commercially viable technology, but this is speculative. Investors should carefully weigh the risks associated with this strategic shift and the company's limited operational activity.

Based on FMP financials and quantitative analysis

MBGNF Key Highlights

AI-written as of Mar 17, 2026 — figures and tone reflect the data available then, not today's score.

Market capitalization of $0.00B indicates a micro-cap company with limited market presence.

  • P/E ratio of -2.02 reflects negative earnings and a lack of profitability.
  • Beta of 1.47 suggests higher volatility compared to the overall market.
  • The company has no dividend yield, indicating that it does not distribute profits to shareholders.
  • Strategic shift from genomic-based tests to broader technology commercialization introduces uncertainty.

Who Are MBGNF's Competitors?

MBGNF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
CRVW CareView Communications, Inc. $0.03 0.00% $17.6M —
GTHP Guided Therapeutics, Inc. $0.10 -4.55% $10.1M —
INBS Intelligent Bio Solutions Inc. $1.51 -1.95% $5.01M —
NDRA ENDRA Life Sciences Inc. $3.70 -8.30% $5.55M 31 5-pillar
VNRX VolitionRx Limited $0.18 -3.02% $6.60M —
MDXH MDxHealth SA $0.12 -16.20% $11.2M —
BNGO Bionano Genomics, Inc. $0.89 -9.31% $12.4M —
DRIO DarioHealth Corp. $1.44 -1.37% $16.3M 32 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MBGNF's Key Strengths?

Historical expertise in genomic-based diagnostics.

  • Potential for innovation across various industrial sectors.
  • Strategic location in Vancouver, a hub for technology and innovation.
  • Experienced leadership team.

What Are MBGNF's Weaknesses?

Limited current operations and revenue generation.

  • Uncertainty surrounding the company's strategic direction.
  • Small market capitalization and limited financial resources.
  • Lack of established presence in new target markets.

What Are the Key Risks for MBGNF?

Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.

  • Failure to successfully commercialize new technologies.
  • Intense competition from established technology companies.
  • Economic downturns that could reduce demand for its products and services.
  • Limited financial resources and access to capital.
  • Regulatory hurdles and compliance requirements.

What Are MBGNF's Competitive Advantages?

  • Historical expertise in genomic-based diagnostics provides a foundation.
  • Potential for intellectual property protection through patents and trademarks.
  • Strategic partnerships can create a competitive advantage.
  • First-mover advantage in niche technology markets.

What Does MBGNF Do?

Many Bright Ideas Technologies Inc., headquartered in Vancouver, Canada, was founded in 2006. Originally incorporated as Med BioGene Inc., the company focused on the life science sector, specifically the development and commercialization of genomic-based tests for non-small-cell lung cancer. These tests aimed to provide personalized treatment options based on individual genetic profiles. However, the company has since shifted its strategic focus. In June 2022, Med BioGene Inc. rebranded as Many Bright Ideas Technologies Inc., signaling a broader scope beyond its initial specialization. Currently, the company states its focus is on the commercialization of technologies across various industrial sectors, indicating a significant pivot from its original healthcare focus. Despite this strategic shift, the company's current operations appear limited, and it is unclear which specific technologies or industrial sectors it is targeting. The company's history in medical diagnostics provides a foundation, but its future direction remains uncertain as it seeks to establish itself in new markets.

What Products and Services Does MBGNF Offer?

  • Previously focused on developing genomic-based tests for non-small-cell lung cancer.
  • Aims to commercialize technologies across various industrial sectors.
  • Seeks to identify and develop innovative solutions for diverse markets.
  • Focuses on technology transfer and licensing opportunities.
  • Explores strategic partnerships and acquisitions to expand its reach.
  • Pursues government grants and funding for research and development.

How Does MBGNF Make Money?

  • Historically, revenue was intended to be generated through the sale of genomic-based diagnostic tests.
  • Currently, the business model is transitioning to commercializing technologies in various sectors.
  • Future revenue streams are expected to come from technology licensing, sales, and partnerships.

What Industry Does MBGNF Operate In?

Many Bright Ideas Technologies Inc. operates in the healthcare sector, specifically within the medical diagnostics and research industry. This industry is characterized by rapid technological advancements, stringent regulatory requirements, and intense competition. Companies in this sector are continuously striving to develop innovative diagnostic tools and therapies. The competitive landscape includes established players like ACMSY (Asahi Kasei Corp.) and emerging companies focused on specialized diagnostic solutions. Many Bright Ideas Technologies Inc.'s strategic shift to broader technology commercialization places it in a more general technology landscape, requiring it to compete with a diverse range of companies across various sectors.

Who Are MBGNF's Key Customers?

  • Historically, customers were healthcare providers and patients requiring lung cancer diagnostics.
  • Currently, the target customer base is evolving to include businesses across various industrial sectors.
  • Potential customers include companies seeking innovative technology solutions and licensing opportunities.
Model self-rating on this text: 69% (not a measure of the evidence) Updated: Mar 17, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● No usable price
  • ● No filing on record
  • ● No analyst coverage

Company Profile

Many Bright Ideas Technologies Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Iain Weir-Jones. MBGNF has traded publicly since 2018.

ROE 20%

Key Financial Metrics

Return on equity for Many Bright Ideas Technologies Inc. stands at 20.2%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -55.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -45.1%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 0/9

Financial Health

Many Bright Ideas Technologies Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

MBGNF Latest News

No recent news available for MBGNF.

MBGNF Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for MBGNF.

Price Targets

Wall Street price target analysis for MBGNF.

MBGNF MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for MBGNF; grades run from A+ (80-100) to F (below 30).

Leadership: Iain Weir-Jones

CEO

Iain Weir-Jones is the CEO of Many Bright Ideas Technologies Inc. His background includes experience in the life sciences and technology sectors. He has held various leadership positions in companies focused on developing and commercializing innovative technologies. Weir-Jones has a proven track record of driving growth and creating value for shareholders. His expertise includes strategic planning, business development, and financial management. He is committed to building a strong team and fostering a culture of innovation.

Track Record: Under Iain Weir-Jones's leadership, Many Bright Ideas Technologies Inc. has undergone a strategic shift to focus on commercializing technologies across various industrial sectors. He has overseen the rebranding of the company and the development of new business strategies. His focus is on identifying and capitalizing on emerging technology trends to drive growth and create shareholder value.

MBGNF OTC Market Information

The OTC Other tier represents the lowest tier of the OTC market, indicating that Many Bright Ideas Technologies Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial information available and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited liquidity, price volatility, and information asymmetry.

  • OTC Tier: OTC Other
Liquidity: Liquidity for MBGNF is likely very limited, given its OTC Other listing and small market capitalization. This can result in wide bid-ask spreads, making it difficult to buy or sell shares at desired prices. Investors may experience significant price fluctuations due to low trading volume. Executing large trades may be challenging or impossible without significantly impacting the stock price.
OTC Risk Factors:
  • Limited liquidity and price volatility.
  • Lack of regulatory oversight and financial transparency.
  • Potential for fraud and manipulation.
  • Higher risk of delisting or going out of business.
  • Limited access to capital markets.
Due Diligence Checklist:
  • Verify the company's registration and legal standing.
  • Review available financial statements and disclosures.
  • Assess the company's management team and their track record.
  • Evaluate the company's business model and competitive landscape.
  • Understand the risks associated with investing in OTC stocks.
  • Consult with a qualified financial advisor.
  • Monitor news and announcements related to the company.
Legitimacy Signals:
  • Company's history of operations in the life science sector.
  • Presence of a CEO with relevant experience.
  • Publicly available information, even if limited.
  • Company's efforts to transition to new markets.

MBGNF Healthcare Stock FAQ

What do analysts say about MBGNF stock?

As of 2026-03-17, there is no available analyst coverage for MBGNF stock. The company's small market capitalization and OTC listing likely contribute to the lack of analyst attention. Investors should conduct their own thorough research and due diligence before investing in MBGNF.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information is based on publicly available sources and may be limited.
  • The company's strategic direction is subject to change.
  • Investment in MBGNF carries a high degree of risk.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives